Home How It Works Who It’s For Who We Are Schedule a Call

Getting your innovation to patients comes down to getting PAID for it.

Savvyn is software that automates evidence aggregation, payer requirements tracking, and complex submissions for Medical Affairs and Market Access teams in diagnostics and medtech.

Schedule a Call
Every source structured, every number traced to the sentence it came from.
Curating the corpus
✓186 claims extracted
●9 flagged for review
206
Sources
9
Needs review
186
Claims extracted
TitleVenueYearStatus
Prospective recurrence surveillance cohortJ Clin Oncol2024Extracted
Imaging vs. molecular surveillance, multi-siteClin Cancer Res2023Needs review
Negative predictive value
97.6% (95% CI 95.9–98.7)
“…a negative surveillance result carried an NPV of 97.6%…” — Results, Table 2
Illustrative — anonymized example
Every intended use, mapped against the bar and everyone who came before you.
Mapping intended uses
✓4 intended uses mapped
●6 competitor products
ScreeningSymptomaticTriage of a massRecurrence
The bar
Show a mortality or treatment-burden benefit from earlier detection.
Standard of care
Routine screening with existing markers not recommended (Grade D).
Guideline / regulatory Competitor Your evidence Milestone
Guideline: Grade D
Landmark RCT: no mortality benefit
Breakthrough designation
2000200820162026
Competitors · 6
Your evidence · 11
Illustrative — anonymized example
Matched against what’s been required before, domain by domain.
Matching to the bar
✓Analytical validity — met
●Clinical utility — partial
Conditionally ready1 critical3 gaps4 minor
Analytical validityMet · CLSI EP05/EP17
Clinical validityMet · 3 cohorts
Clinical utilityPartial · 2 studies
Critical Clinical utility

No study yet links a test-guided management change to a measured outcome benefit.

RemediationProspective observationalTimeline12–24 moFeasibilityHigh
Illustrative — anonymized example
Where you’re covered, where competitors are, and where the gap is.
Mapping coverage
✓Medicare — 2 indications
●Commercial — mostly silent
Medicare coveredNot coveredCommercial
TestInd. AInd. BInd. CInd. D
Your assayYours——
Competitor A
Competitor B
Competitor C——
2indications where you hold Medicare coverage and no competitor does — commercial policy still the open gap.
Illustrative — anonymized example
Ask a question. Get an answer built from your evidence, cited line by line.
Assembling an answer
✓3 studies matched
●1 graded uncertain
✦Which of our studies answers a clinical-utility denial?

Two of your studies speak directly to the utility criterion the payer cited; a third supports it only indirectly.

1Prospective cohort, 412 pts — management change reported [p. 6]Strong
2Multi-site retrospective — lead time vs. imaging [Table 3]Moderate
3Case series, n=18 — endpoint unclear [Abstract]Uncertain
Illustrative — anonymized example
Submission drafts that update themselves when the evidence does.
Drafting the dossier
✓2 sections up to date
●3 sections pending
Technical assessment · 7 sections3 pending
1.Executive summary✓ Up to date
3.Analytical & clinical validation2 pending
4.Test performance vs. standard of care3 pending
Proposed change · triggered by new publication, 2h ago specificity of approximately 98.2% (95% CI 95.4–99.4%)
HoldAccept
Illustrative — anonymized example
Always on

Runs continuously, updates the moment anything changes.

New publications, payer policy changes, competitor moves — Savvyn re-triggers the moment the landscape shifts, so your evidence position is never a snapshot from last quarter.

See how it works, continuously →
Recent activity
2h agoPayer policy updated — Regional MACApplied
6h agoNew publication ingested — Clin Cancer ResIngested
1d agoCoverage criteria changed — Regional BCBSReviewing
2d agoDossier section 3 flagged for reviewReview
Why Savvyn

Everyone else solves pieces. Savvyn owns the whole workflow.

Consultants bring the expertise, but not the speed. General-purpose AI brings the speed, but not the expertise or the audit trail. Savvyn brings both.

SavvynConsultantsGeneral AI
Evidence-to-access expertise✓✓—
Fast and on demand✓—✓
Live, continuously updated✓——
Every claim traced to its source✓●—
✓ Full ● Partial — Not offered Based on publicly described capabilities.
Why trust it

Don’t take our word for it.

Every claim is traced back to its source and independently validated — so you’re never guessing whether it’s right.

99.4%
Citation traceability — every claim linked to its source.
0.8%
Hallucination rate, independently measured.
673
Corpus elements validated under a Maine Technology Institute feasibility grant.
The value prop

The ROI isn’t just cost savings.

It’s bringing the revenue event forward, cutting the manual work it takes to get there, and de-risking your next raise.

Schedule a Call
Faster
Revenue accelerated
Shorter time to coverage brings the revenue event forward.
Cheaper
Cost reduced
Replaces most of the manual evidence work you pay for today.
De-risked
Investment de-risked
The evidence standard that wins coverage wins your raise, too.
Who it’s for

Built for the people who own the evidence.

Medical Affairs, Market Access, and early founding teams — Savvyn shows up differently at every stage of the evidence lifecycle, from scoping your first indication to appealing your last denial.

Medical Affairs
Know what your evidence already proves, and where the real gaps are, before the payer asks.
Market Access
Walk into every submission knowing exactly what’s been required before, and how you measure up.
Early Founding Teams
Scope your first indication with the same evidence discipline as teams five years ahead of you.
See what Savvyn does for your role →

You don’t get paid for innovating. You get paid for proving it works.

Schedule a Call